Hiv protease inhibitors and glucose metabolism

AIDS

Volumn 16, Issue 6, 2002, Pages 925-926

  Grunfeld, Carl ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glucose transport; Glut4; HIV; Indinavir; Insulin; Protease inhibitors

Indexed keywords

PROTEINASE INHIBITOR;

DISEASE ASSOCIATION; EDITORIAL; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; PRIORITY JOURNAL; TREATMENT PLANNING;

GLUCOSE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR;

EID: 0037066358     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200204120-00013     Document Type: Editorial

References (11)

1. Fat distribution and metabolic changes in patients with HIV infection
2. 'Buffalo hump' in men with HIV-1 infection
3. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
4. The mechanism of insulin resistance caused by HIV protease inhibitor therapy
5. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations
6. Metabolic effects of indinavir in healthy HIV-seronegative men
7. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort study
8. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
9. Indinavir induces acute and reversible insulin resistance in rats
10. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study
11. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors